SSC Subcommittee Program, Monday 24 May
Animal Models
Chairman: Timothy Nichols (US)
Co-chairmen: Edward Conway (CA), Shaun Coughlin (US), Jay Degen (US), Nigel Mackman (US), Eva-Maria Muchitsch (AT), Susan Smyth (US), Hugo Ten Cate (NL), Hartmut Weiler (US)
|
Standardization of the Murine Tail Bleeding Model –This short manuscript will be submitted soon. |
9:00 |
|
Models of clotting in Murine Atherosclerosis |
9:30 |
|
Mouse Models of von Willebrand Disease |
10:00 |
|
Sensitivity of the Whole Blood Clotting Time to F.IX in Canine hemophilia B–will present this project as a candidate for the short manuscript. |
10:30 |
|
Ferric chloride arterial thrombosis standardization |
11:00 |
|
Plans for Animal Models Subcommittee Meeting at XXIII ISTH 2011, Kyoto Japan |
11:15 |
Control of Anticoagulation, Session 2
Chairman: Trevor Baglin (UK)
Co-chairmen: Walter Ageno (IT), Job Harenberg (DE), Clive Kearon (CA), John Olson (US), Gualtiero Palareti (IT), Sam Schulman (CA), Antonius Van Den Besselaar (NL)
|
Update on the development of generic low molecular weight heparins and adherence to recommendations of scientific organizations |
09:00 |
|
Report of the working party on standardization of methods to determine direct factor Xa inhibitors |
09:20 |
|
Differential Effects of Various Anticoagulants as measured by Thromboelastography. |
9:40 |
|
Thrombin generation in orthopaedic patients receiving rivaroxaban |
10:00 |
|
Discussion and Summary |
10:20 |
|
Coffee break |
10:40 |
|
Long term control of anticoagulation in patients with thrombosis in unusual sites
|
11:00 |
|
New oral Anticoagulants - Round table discussion including:
|
12:00 |
|
Planning of future SSC activities |
12:45 |
Chairman: Hideo Wada (JP)
Co-chairman: Hunn Kyung Kim (KR), Jorn Dalsgarrd Nielsen (DK), Jecko Thachil (UK), Cheng-Hock Toh (UK)
|
Diagnosis and Treatment |
|
|
Chairman’s report |
09:00 |
|
British Society for Standards in Hematology Guideline in DIC |
09:10 |
|
Japanese guideline on DIC |
09:30 |
|
Discussion |
09:45 |
|
Educational session (80 min) |
|
|
Pathogenetic role of alarmin, HMGB1 in DIC |
09:50 |
|
Pathophysiological consideration in sepsis-induced DIC. |
10:20 |
|
DIC due to tropical disease |
10:35 |
|
Discussion |
10:55 |
|
Coffee break? |
|
|
Standardization issues (100 min) |
|
|
Considerations on the use of the ISTH non-overt DIC scoring system |
11:15 |
|
Evaluation of modified non-overt DIC criteria on the prediction of the poor-outcome in patients with sepsis |
11:35 |
|
Effect of cardiopulmonary bypass on activated partial thromboplastin time waveform analysis, serum procalcitonin and C-reactive protein concentrations.Maxime Cannesson (FR) |
11:55 |
|
Working group on Clt WF analysis |
12:15 |
|
Accuracy of platelet counting by the automated hematologic analyzers disseminated intravascular coagulation: potential effects of platelet activation on the platelet measurement |
12:25 |
|
Prospective study in Japan |
12:45 |
|
Discussion |
12:55 |
Predictive Variables in Cardiovascular Disease
Chairman: James Douketis (CA)
Co-chairmen: Gordon Lowe (UK), Frederick Spencer (CA), Alberto Tosetto (IT), Richard White (USA)
|
Part A: Update of SSC-related Activities (15 min presentations + 5 min QA) |
|
|
Factor IX Malmö and recurrent VTE |
9:00 |
|
MicroRNA and venous thrombosis |
9:20 |
|
D-dimer and Recurrent VTE Collaborative Group |
9:40 |
|
New molecular markers of CV disease |
10:00 |
|
Global tests to predict VTE |
10:20 |
|
Residual vein thrombosis and recurrent thrombosis |
10:40 |
|
Coffee break |
11:00 |
|
Part B: Educational Session (20 min presentations + 5 min QA) and Debate (15 min presentations + 5 min rebuttals ´ 2) |
|
|
Established CV risk factors |
11:20 |
|
New and emerging CV risk factors |
11:45 |
|
Should CRP be used in everyday practice to risk-stratify patients without established CV disease? Yes |
12:10 |
|
Should CRP be used in everyday practice to risk-stratify patients without established CV disease? No |
12:30 |
Von Willebrand Factor, Session 2
Chairman: Jeroen Eikenboom (NL)
Co-chairmen: Thomas Abshire (US), Imre Bodo (HU), Giancarlo Castaman (IT), Jorge DiPaola (US), Emmanuel J Favaloro (AU), Anne Goodeve (UK), Bernhard Lämmle (CH), David Lillicrap (CA), Reinhard Schneppenheim (DE)
|
ADAMTS13 |
|
|
Fluorogenic and chromogenic assays of ADAMTS13 activity. |
9:00 |
|
VWF and ADAMTS13 interactions |
9:15 |
|
Discussion |
9:30 |
|
VWF and VWD registries |
|
|
Platelet Type - VWD registry |
9:40 |
|
VWF Mutation database Need for a steering committee Publication/report on database |
10:00 |
|
Discussion |
10:20 |
|
Coffee break |
|
|
Maintenance of Websites of different Working Parties - www.ddavp-in-vwd.com Working party on desmopressin in the management of VWD - www.intreavws.com International registry on acquired VWD - www.vwfassays-in-vwd.com Working party on VWF assays in VWD diagnosis |
10:50 |
|
Discussion |
11:00 |
|
Ongoing and starting multicenter studies on VWD |
|
|
Working party on desmopressin in the management of VWD Publication/report |
11:10 |
|
Working party on VWF assays in VWD diagnosis Publication/report |
11:20 |
|
European Project on type 3 VWD |
11:30 |
|
EU VWD Cooperative Group |
11:45 |
|
Zimmerman Project (ZPMCB-VWD) |
12:00 |
|
GWAS on VWD/bleeding phenotype |
12:10 |
|
VWD International Prophylaxis (VIP) Study |
12:20 |
|
WIN (Willebrand in Netherlands) |
12:35 |
|
Discussion |
12:50 |
Biorheology
Chairman: Johan Heemskerk (NL)
Co-chairmen: Lawrence Brass (US), Thomas Diacovo (US),
|
Session 1. Thrombus formation: novel methods and standardization |
|
|
Towards standardization of biorheological assays – opening remarks |
15.00 |
|
Time-resolved measurement of thrombus formation on a microfluid biochip |
15.10 |
|
Use and potential for flow devices in measurement of thrombus formation |
15.30 |
|
Microfluidic high throughput assays of platelet adhesion |
15.50 |
|
Fibrin formation and thrombus stability under flow |
16.10 |
|
Possibilities and limitations in the standardization of in vivo thrombosis studies in mouse |
16.30 |
|
Coffee break |
|
|
Session 2. Blood flow-dependent processes in vitro and in vivo: novel concepts |
|
|
Lessons learned from the measurement of platelet adhesion receptor kinetics |
17.10 |
|
Platelet adhesion kinetics: from mathematical modeling to in vivo relevance |
17.30 |
|
Microfluidic assays to study local disturbances in blood rheology on platelet adhesion and aggregation |
17.50 |
|
Thrombus formation and plaques in vivo and in vitro |
18.10 |
|
Role of ADAMTS13 in flow-dependent thrombus formation |
18.30 |
|
Final discussion and closing remarks |
18.50 |
Chair: Alok Srivastava (IN)
Co-Chair: Jan Astermark (SE), Kathelijn Fischer (NL), Charles Hay (UK), Claude Negrier (FR), Johannes Oldenburg (DE), Flora Peyvandi (IT), Edward Tuddenham (UK), Leonard Valentino (US)
|
Welcome and Introductions |
|
|
Completed/Submitted reports and new developments. Alok Srivastava (IN) |
|
|
Section I - Rare Bleeding Disorders |
|
|
Overview |
15:10 |
|
European network of RBDs (EN-RBD): Results of the collaboration at 3 years. |
15:15 |
|
RBD – the WFH database. |
15:30 |
|
Bleeding scores in RBD. |
15:45 |
|
Evaluation of F XIII deficiency – Available assays and their limitations. |
16:00 |
|
Monitoring hemostasis during surgery in FXI deficiency. |
16:15 |
|
Definitions in rare bleeding disorders – Report of the working group. |
16:30 |
|
General discussion / Future directions |
16:50 |
|
Coffee break |
|
|
Section II - Factor VIII/IX: Clinical issues- I (Assay/EQA/Phenotype) |
|
|
Overview: Tests of global hemostasis and their applications. |
17:20 |
|
Towards standardization of TGT - Report of the working party. |
17:25 |
|
Towards standardization of TEG - Report of the working party. |
17:45 |
|
Towards standardization of clot wave form analysis - Report of the working party. |
18:05 |
|
Could global haemostasis tests be used to tailor treatment in hemophilia? |
18:25 |
|
General discussion / Future directions |
18:45 |
Lupus Anticoagulants/Phospholipid-dependent Antibodies
Chairman: Thomas L Ortel (US)
Co-Chairmen: Ph de Groot (NL), Bas de Laat (NL), Vittorio Pengo (IT), Jacob Rand (US), Guido Reber (CH), Armando Tripodi (IT)
|
Updates from the APS Meeting in Galveston |
15:00 |
|
Diagnosis of APS: Proposed Consensus Document |
15:25 |
|
Is a single positive test sufficient to diagnose APS? |
15:55 |
|
Lupus anticoagulant: an attempt at standardization |
16:25 |
|
Coffee break |
16:45 |
|
b2 glycoprotein I conformation and antibody recognition |
17:00 |
|
Human monoclonal antibody standards for antiphospholipid antibody testing |
17:30 |
|
Developing the annexin A5 inhibition assay for clinical laboratory use |
17:45 |
|
Clinical and Laboratory Issues in APS: Special Populations
· Obstetrical complications and APS |
18:15 |
Chairman: Marco Cattaneo (IT)
Co-chairmen: Christian Gachet (FR), Paolo Gresele (IT), Paul Harrison (UK), Catherine Hayward (CA), Dermot Kenny (IR), Alan Michelson (US), Diane Nugent (US), Stephen Watson (UK)
|
First Session |
|
|
Inherited platelet function disorders: an overview |
15:00 |
|
Diagnosis of platelet function disorders |
15:30 |
|
Update on standardized bleeding scores for patients with defects of primary hemostasis |
16:00 |
|
Organization of the Working Party on Diagnosis of platelet function disorders GENERAL DISCUSSION |
16:30 |
|
Coffee break |
17:00 |
|
Second Session |
|
|
Factors influencing the individual response to clopidogrel |
17:30 |
|
The use of laboratory tests of platelet function to assess the bleeding risk in patients on treatment with thienopyridines |
18:00 |
|
Final report of the Working Party on LTA Standardization Marco Cattaneo (IT), on behalf of the Working Party on LTA standardization (Chiara Cerletti (IT), Paul Harrison (UK), Catherine PM Hayward (CA), Dermot Kenny (IR), Alan D Michelson (US), Diane Nugent (US), Paquita Nurden (FR), Koneti A Rao (US), Alvin Schmeier (US), Steve Watson (UK)): |
18:30 |
Women’s Health Issues on Thrombosis and Haemostasis
Chairman: Sabine Eichinger (AT)
Co-chairmen: Margareta Blomback (SE), Benjamin Brenner (IL), Jacqueline Conard (FR), Andra James (US), Barbara Konkle (US), Peter Kouides (US), Claire McLintock (NZ), Claire Philipp (US)
|
Welcome and Introduction of Co-chairmen Program Overview |
|
|
Educational activities |
|
|
Educational Program of SSC Meetings: Overview and future perspectives |
15:05 |
|
Report on the Women’s Health Issues in Thrombosis and Haemostasis symposia 2009 and 2011 |
15:10 |
|
ISTH educational activities for developing countries |
15:15 |
|
SSC initiated projects – part I |
|
|
Type 1 VWD in Pregnancy |
15:20 |
|
Diagnosis of deep-vein thrombosis and pulmonary embolism in pregnancy - an update |
15:35 |
|
Contraception and the risk of venous thromboembolism: Practical considerations in high-risk women |
16:00 |
|
Update on Registries |
|
|
Overview of past registries; future perspectives |
16:20 |
|
Coffe break |
16:30 |
|
SSC initiated projects – part II Spotlight on “Thrombophilia and pregnancy outcomes” |
|
|
The relevance of thrombophilic risk factors and pregnancy outcomes |
16:50 |
|
Aspirin and Aspirin Combined with Low-Molecular-Weight Heparin in Women with Unexplained Recurrent Miscarriage: a Randomized Controlled Multicenter Trial (ALIFE Study) |
17:15 |
|
Menorrhagia Working Group |
|
|
Standardized Bleeding Scores |
17:35 |
|
The risk of miscarriage in women with rare bleeding disorders |
17:50 |
|
More health challenges for women with hereditary bleeding disorders in communities where fertility is essential |
18:10 |
|
New projects |
|
|
Travel and thrombosis in women |
18:30 |
|
Assay of TF and TFPI on microparticles in pregnancy complications |
18:40 |
|
Closing Remarks |
18:50 |